Diagnosis and Management of Hypertrophic Cardiomyopathy
For patients with suspected HCM, obtain a transthoracic echocardiogram (TTE) as the primary diagnostic test, along with a 12-lead ECG and 24-hour Holter monitoring to detect ventricular arrhythmias and assess sudden cardiac death risk 1.
Initial Diagnostic Workup
Essential Components
The diagnostic evaluation must include:
- Physical examination: Look specifically for a harsh crescendo-decrescendo systolic murmur (indicating LVOTO), prominent apical point of maximal impulse, and abnormal carotid upstroke 2
- Three-generation family history: Document any relatives with HCM, unexplained sudden death, or early cardiac events 1, 2
- 12-lead ECG: Required in all suspected cases 3
- 24-hour Holter monitoring: Essential at initial evaluation to detect ventricular tachycardia and identify ICD candidates 3
- Transthoracic echocardiogram: The cornerstone diagnostic test 1
When Echocardiography is Inconclusive
If TTE findings are inconclusive or cannot adequately visualize the myocardium, cardiac MRI (CMR) is indicated for diagnostic clarification 1. CMR is particularly useful for:
- Apical HCM variants
- Atypical patterns of hypertrophy
- Distinguishing HCM from infiltrative diseases (amyloidosis, Fabry disease, LAMP2 cardiomyopathy) 3
Provocative Testing for LVOTO
For patients with resting left ventricular outflow tract gradient <50 mm Hg, perform TTE with provocative maneuvers (Valsalva, squat-to-stand) 1. If symptoms persist without demonstrable gradient, exercise TTE is recommended to detect and quantify dynamic LVOTO 1.
Genetic Testing and Family Screening
Index Patient
Genetic testing is reasonable in the index patient to facilitate identification of at-risk first-degree family members 3. However, genetic testing should NOT be used for sudden cardiac death risk stratification, as its usefulness for this purpose is uncertain 3.
Family Screening Protocol
Screen all first-degree relatives with ECG and TTE 3. The timing depends on age 2:
- Pediatric patients: Begin screening when HCM is diagnosed in a family member; repeat every 1-2 years
- Children/adolescents: Screen no later than puberty; repeat every 2-3 years
- Adults: Screen at diagnosis of family member; repeat every 3-5 years
Important caveat: Ongoing clinical screening is NOT indicated in genotype-negative relatives in families with known HCM mutations 3.
Ongoing Surveillance
Stable Patients
Repeat TTE every 1-2 years in clinically stable patients to assess:
- Degree of myocardial hypertrophy
- Dynamic LVOTO
- Mitral regurgitation severity
- Myocardial function 1
Repeat 24-hour Holter monitoring every 1-2 years to screen for asymptomatic paroxysmal atrial fibrillation 3.
Symptomatic Changes
Obtain repeat TTE and ECG immediately when patients develop new symptoms or clinical events 1, 3.
Medical Management
Symptomatic Obstructive or Nonobstructive HCM
Beta-blockers are the first-line treatment for symptoms (angina or dyspnea) 3. Titrate to a resting heart rate of <60-65 bpm, up to maximum recommended doses 3.
If beta-blockers are ineffective or contraindicated, use verapamil (starting low and titrating up to 480 mg/day) 3. Critical warning: Use verapamil with extreme caution in patients with high gradients, advanced heart failure, or sinus bradycardia 3.
For persistent symptoms despite beta-blockers or verapamil alone, add disopyramide 3. This combination approach is reasonable for refractory symptoms in obstructive HCM.
Acute Management
For acute hypotension in obstructive HCM not responding to fluids, administer intravenous phenylephrine (or another pure vasoconstrictor) 3.
Septal Reduction Therapy
Septal reduction therapy (surgical myectomy or alcohol septal ablation) should ONLY be performed at experienced comprehensive or primary HCM centers with demonstrated excellence in clinical outcomes 1.
Procedural Guidance
- Surgical myectomy: Requires intraoperative transesophageal echocardiogram (TEE) to assess mitral valve anatomy and adequacy of myectomy 1, 3
- Alcohol septal ablation: Requires TTE or TEE with intracoronary contrast injection of candidate septal perforators 1, 3
- Post-procedure: Obtain TTE within 3-6 months to evaluate procedural results 1
Critical pitfall: Septal reduction therapy should NOT be performed in asymptomatic patients with normal exercise capacity, regardless of gradient 3.
Lifestyle Modifications
Exercise Restrictions
Patients with HCM must avoid competitive sports activities 4. However, low-intensity aerobic exercise is reasonable as part of a healthy lifestyle 3.
Dietary Considerations
- Avoid large meals in patients with LVOTO, as they can precipitate chest pain; recommend smaller, more frequent meals 4
- Avoid dehydration and excess alcohol, particularly with LVOTO 4
- Manage constipation (common with verapamil/disopyramide) with diet and aperients 4
Medication Precautions
Avoid PDE5 inhibitors and peripheral vasodilators, especially in patients with LVOTO 4.
Endocarditis Prophylaxis Consideration
Infective endocarditis in HCM is virtually confined to patients with LVOTO, particularly those with left atrial dilation. The incidence is 3.8 per 1000 person-years with a 4.3% probability at 10 years 4. Endocardial lesions typically occur on the thickened anterior mitral leaflet or proximal ventricular septum.
Referral to HCM Centers
Referral to a comprehensive HCM center is reasonable for:
- Complex disease-related management decisions
- Candidates for septal reduction therapy
- Challenging ICD decision-making
- Genetic counseling
- Sports participation counseling 1, 2
The 2020 AHA/ACC guidelines 1 represent the most recent comprehensive recommendations and should guide current practice, with the 2024 update 2 providing additional refinements in screening protocols and center-based care.